Overall, aberrant amplification, deletion, or mutation of at least one receptor tyrosine kinase (RTK) has been found in 67.3% of GBM, with EGFR accounting for 57.4% (10) (as shown in Figure 1). This evidence concerns the gene EGFR and glioblastoma.